Modeling Pharmacogenomics' Impact
Executive Summary
With the intuitive appeal of pharmacogenomics (PGX) now largely accepted, pharmaceutical companies are wrestling with whether and how to incorporate PGX information into their drug discovery, development, and marketing processes. Yet largely absent from the advocacy of the pharmacogenomicists is a detailed discussion of the impact PGX could have on market share and average drug revenues. Based on discussions with industry leaders and using data from markets for certain existing drugs, the authors, members of the consultancy AT Kearney, developed a set of assumptions and constructed a framework to quantify the impact of PGX on both the revenues of the average drug and on the overall size of the pharmaceutical market for a given indication.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.